Corcept Therapeutics Director James N. Wilson Sells 10,000 Shares Under 10b5-1 Plan

James N. Wilson, a director of Corcept Therapeutics Inc., sold 10,000 shares of common stock on June 16, 2026, through two transactions executed under a pre-established 10b5-1 trading plan. The sales consisted of 4,177 shares at a weighted average price of $82.6948 and 5,823 shares at $83.5708. Following these transactions, Wilson's direct holdings decreased to 1,094,543 shares. Additionally, Wilson holds indirect interests through two grantor retained annuity trusts, each owning 200,000 shares, over which he has voting power but disclaims beneficial ownership except for his pecuniary interest. The sales were made pursuant to a 10b5-1 plan adopted on March 12, 2026, and the filing includes standard disclaimers regarding beneficial ownership of trust-held shares.